Clinical Trial Update: An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer [Phase 2]

View source ↗

Summary

Open-label Phase 2 window-of-opportunity study evaluating ganetespib in women with breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Ganetespib (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Status: COMPLETED